CEL-SCI Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $48.5M
- Price
- $2.74
- % Change (Daily % change from the live per-ticker quote feed.)
- +13.22%
- Volume
- 470.2K
About
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Quick stats
Shares outstanding17.7M
Computed float16.6M
Float / shares93.8%
Cash runway (months)1.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000725363
Websitehttps://cel-sci.com
AI Summary
AI-generated1/15
minorbullishclinical trial
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
CEL-SCI said Chief Scientific Officer Dr. Eyal Talor will deliver a keynote at the 6th World Congress on Otology, Rhinology and Laryngology in Rome on October 26-27, 2026, presenting new analyses from the Multikine Phase 3 study that have not previously been shown.
The keynote centers on a biomarker-based patient selection method that identifies head and neck cancer patients most likely to gain a survival benefit from Multikine, and it forms the foundation of the upcoming 212-patient U.S. Confirmatory Registration Study designed with approximately 97% statistical power.
In the completed Phase 3, described as the world's largest for locally advanced head and neck cancer, Multikine raised 5-year survival to 73% versus 45% with standard of care alone and halved the risk of death from 55% to 27%. Multikine remains investigational and has not been licensed or approved by the FDA or any other regulatory agency.
Red flags
- Multikine is investigational — not FDA approved and safety/efficacy not established; Phase 3 survival figures will need confirmation in the upcoming registrational study
- Promotional keynote release with no new data disclosed until the October 26-27 conference
- Boilerplate risk language flags inability to raise necessary capital and inability to finalize a partnering agreement